<DOC>
	<DOCNO>NCT00352053</DOCNO>
	<brief_summary>The purpose study assess safety efficacy tenofovir disoproxil fumarate ( tenofovir DF ; TDF ) plus genotype-guided optimized background regimen ( OBR ) compare placebo plus OBR treatment human immunodeficiency virus type 1 ( HIV-1 ) infect antiretroviral treatment-experienced adolescent plasma HIV-1 ribonucleic acid ( RNA ) level great equal 1000 copies/mL .</brief_summary>
	<brief_title>Safety Efficacy Tenofovir DF HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy</brief_title>
	<detailed_description>This 48-week , randomize , double-blind , placebo-controlled , multicenter study safety efficacy tenofovir DF part optimize antiretroviral regimen HIV-1 infect adolescent ( 12 year &lt; 18 year age ) fail current antiretroviral regimen HIV-1 RNA level ≥ 1000 copies/mL screen . Data three consecutive 96-week study extension use evaluate long-term efficacy , safety , tolerability open-label tenofovir DF part antiviral regimen , provide data 336 week total drug exposure . Pretreatment : HIV-1 genotyping perform part screen assessment assist construction OBR , define least 3 , 5 antiretroviral agent , include tenofovir DF placebo . Randomized Phase : Participants randomize 1:1 ratio receive either tenofovir DF + OBR , placebo + OBR . The majority efficacy safety assessment perform clinic visit ( Weeks 4 , 8 , 16 , 24 , 32 , 40 , 48 ) . At Week 24 , participant adherent study drug ( opinion investigator ) , demonstrate ≥ 0.5 log10 copies/mL decrease baseline HIV-1 RNA , consider nonresponders unblinded . Nonresponders randomize placebo group give option continue study receive open-label tenofovir DF appropriate background regimen determine investigator . Nonresponders randomize tenofovir DF treatment group discontinue study . Extension Phases : After complete 48 week double-blind treatment tenofovir DF placebo , participant reach 18 year age , , opinion investigator , would derive clinical benefit use open-label tenofovir DF , give option continue ( initiate ) treatment open-label tenofovir DF first three 96 week study extension period . Nonresponders receive open-label tenofovir DF Week 24 also consider eligible first study extension meet criterion Week 48 . After complete first 96 week study extension , participant reach 18 year age , show ongoing clinical benefit tenofovir DF , give option continue receive open-label tenofovir DF additional 96 week tenofovir DF become commercially available country participant enrol , whichever occur first . After complete second 96 week study extension , participant reach 18 year age , show ongoing clinical benefit tenofovir DF , give option continue receive open-label tenofovir DF additional 96 week tenofovir DF become commercially available country participant enrol , whichever occur first . Presentation data : After randomize phase study , participant randomize placebo randomize phase study switch open-label tenofovir DF baseline reset ( define open-label baseline ) , outcome data collect ( on/after adverse event ( AEs ) /concomitant medication ) participant receive first dose open-label tenofovir DF include .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Major Weight ≥ 35 kg Documented laboratory diagnosis HIV infection Plasma HIV1 RNA ≥ 1000 copies/mL Prior antiretroviral treatment experience least 2 antiretroviral drug class Naive tenofovir DF Absence K65R mutation genotypic test Patients require didanosine background regimen Prior history significant renal disease Prior history significant bone disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>Randomized , Double-Blind</keyword>
	<keyword>Control</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>OBR</keyword>
	<keyword>Optimized background regimen</keyword>
	<keyword>Highly Active Antiretroviral Therapy</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Virus</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>Virus</keyword>
	<keyword>Human Immunodeficiency</keyword>
	<keyword>Pediatrics</keyword>
</DOC>